Tyrosine Kinase Inhibitors: Global Market Outlook

This report provides a detailed understanding of the current market scenario for tyrosine kinase inhibitors and an assessment of the market’s growth over the period from 2023 through the end of 2028. The report highlights major trends and challenges that affect the global market and the vendor landscape.

Report Scope:

In this report, the market has been segmented based on type, application and geography. The report provides an overview of the global tyrosine kinase inhibitor market and analyzes market trends. Using 2022 as the base year, the report provides estimated market data for the forecast period of 2023 through 2028. Market values have been estimated based on the total revenue of tyrosine kinase inhibitor product providers.

The report covers the market for tyrosine kinase inhibitors with regard to the user base across different regions. It also highlights major trends and challenges that affect the market and the vendor landscape. The report estimates the global market for tyrosine kinase inhibitors in 2022 and provides projections for the expected market size through 2028. The scope of the study includes tyrosine kinase inhibitor drugs that are already available in the market as well as future prospects.

Report Includes:

An overview of the global market for tyrosine kinase inhibitors
Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Definition of tyrosine kinase inhibitors and their characteristics, and coverage of the market's dynamics, specifically drivers, inhibitors and opportunities
Discussions of novel tyrosine kinase inhibitors and their utility in the human trials
Examination of the technologies and methods used for the creation of novel targets and their therapeutic approaches
Discussions of market challenges and how to overcome them if the market is to reach its commercialization potential, pipeline drugs and relevant patents
Information on recent mergers and acquisitions, collaborations, partnerships and product introductions
Profiles of major players in the market

Product Code: BIO242A

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Geographic Breakdown
Segmentation Breakdown

Chapter 2 Summary and Highlights

Market Outlook
Market Summary

Chapter 3 Market Overview

Kinase Inhibitors
Types of Kinase Inhibitors
Tyrosine Kinase Inhibitors
Regulatory Scenario
Market Dynamics
Drivers
Restraints
Opportunities

Chapter 4 Market Breakdown by Type and Application

Market for Tyrosine Kinase Inhibitors, by Type
Receptor Tyrosine Kinase Inhibitors
Non-receptor Tyrosine Kinase Inhibitors
Market for Tyrosine Kinase Inhibitors, by Application
Lung Cancer
Chronic Myelogenous Leukemia (CML)
Others

Chapter 5 Market Breakdown by Region

Global Market for Tyrosine Kinase Inhibitors, by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 6 ESG Development

Introduction to ESG
The Sustainability of Tyrosine Kinase Inhibitor Manufacturers in the Industry
Pharma End User Sustainability in the Industry
Case Study
BCC Research Viewpoint

Chapter 7 Industry Structure

Ranking of Top Companies
Pipeline Analysis
Patent Analysis
Emerging Trends

Chapter 8 Company Profiles

ASTRAZENECA
BAYER AG
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB CO.
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
NOVARTIS AG
PFIZER INC.

Product Code: BIO242A

List of Tables

Summary Table : Global Market for Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 1 : Characteristics of ATP-competitive and Non-ATP Competitive Inhibitors
Table 2 : Types of Receptor Tyrosine Kinase Inhibitors
Table 3 : Types of Non-receptor Tyrosine Kinase Inhibitors
Table 4 : FDA-approved Kinase Inhibitors, 2001-2021
Table 5 : FDA-approved Tyrosine Kinase Inhibitors and Their Drug Targets
Table 6 : EMA-approved Kinase Inhibitors, 2001-2020
Table 7 : Patent Expiration Dates of Tyrosine Kinase Inhibitors
Table 8 : Global Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 9 : Global Market for Receptor Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 10 : Global Market for Non-receptor Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 11 : Approved Tyrosine Kinase Inhibitors and Their Targets and Indications
Table 12 : Global Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 13 : Global Market for Tyrosine Kinase Inhibitors Used to Treat Lung Cancer, by Region, Through 2028
Table 14 : Global Market for Tyrosine Kinase Inhibitors Used to Treat CML, by Region, Through 2028
Table 15 : Global Market for Tyrosine Kinase Inhibitors Used in Other Applications, by Region, Through 2028
Table 16 : Global Market for Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 17 : North American Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 18 : North American Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 19 : North American Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 20 : European Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 21 : European Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 22 : European Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 23 : Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 24 : Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 25 : Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 26 : Rest of the World Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 27 : Rest of the World Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 28 : Key Focus Areas in ESG Metrics
Table 29 : ESG Rankings for Major Pharma Companies Manufacturing TKIs, 2023
Table 30 : Revenue from Sales of Selected Tyrosine Kinase Inhibitors, 2020-2022
Table 31 : Ongoing Clinical Trials of Various Tyrosine Kinase Inhibitors
Table 32 : Patents Filed on Tyrosine Kinase Inhibitors, 2018-2022
Table 33 : AstraZeneca: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 34 : Bayer AG: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 35 : Boehringer Ingelheim International GmbH: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 36 : Bristol-Myers Squibb Co.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 37 : Eisai Co. Ltd.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 38 : F. Hoffmann-La Roche Ltd.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 39 : Johnson & Johnson Services Inc.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 40 : Novartis AG: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 41 : Pfizer Inc.: Tyrosine Kinase Inhibitor Drug Product Portfolio

List of Figures

Summary Figure A : Global Market Shares of Tyrosine Kinase Inhibitors, by Region, 2022
Summary Figure B : Growth Rate of North America, Europe, and Asia-Pacific Markets for Tyrosine Kinase Inhibitors, 2023-2028
Figure 1 : Share of Estimated Number of New Cancer Cases Among Women, by Cancer Type, 2020
Figure 2 : Share of Estimated Number of New Cancer Cases Among Men, by Cancer Type, 2020
Figure 3 : National Cancer Institute Research Funding, 2012-2019
Figure 4 : Global Market Shares of Tyrosine Kinase Inhibitors, by Type, 2022
Figure 5 : Global Market Shares of Tyrosine Kinase Inhibitors, by Application, 2022
Figure 6 : Global Mrket for Tyrosine Kinase Inhibitors, by Region
Figure 7 : Global Market Shares of Tyrosine Kinase Inhibitors, by Region, 2022
Figure 8 : Global Market Shares of Tyrosine Kinase Inhibitors by Region, 2028
Figure 9 : How a Strong ESG Proposition Benefits Businesses
Figure 10 : The 10 Business Sustainability Trends Identified for 2022
Figure 11 : ESG Adoption Level Across All Industries, 2021 and 2022
Figure 12 : Key Sustainable Practices Being Implemented in Research Laboratories
Figure 13 : ESG Commitments of Pfizer
Figure 14 : Company Shares of the Market for Tyrosine Kinase Inhibitors, 2022
Figure 15 : Distribution Share of Clinical Trial Phases of Various Tyrosine Kinase Inhibitors
Figure 16 : Number of Patents Filed, Granted and Published, 2018-March 2023
Figure 17 : Timeline of Kinase Inhibitors, Since 2001

Tyrosine Kinase Inhibitors: Global Market Outlook

Description

Table of Contents

List of Tables

Highlights:

Report Scope:

Report Includes:

Table of Contents

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

Chapter 4 Market Breakdown by Type and Application

Chapter 5 Market Breakdown by Region

Chapter 6 ESG Development

Chapter 7 Industry Structure

Chapter 8 Company Profiles

List of Tables

List of Figures